Single-centre, retrospective study to evaluate long-term clinical outcomes of the anti-TNF-alpha monoclonal antibody, adalimumab, in patients with psoriasis (PsO) or psoriatic arthritis (PsA).
Phase of Trial: Phase IV
Latest Information Update: 31 May 2017
At a glance
- Drugs Adalimumab (Primary)
- Indications Psoriasis; Psoriatic arthritis
- Focus Therapeutic Use
- 31 May 2017 New trial record